iRhythm Holdings, Inc. announced the acquisition of VitalConnect, Inc. for $287.5 million, significantly expanding its remote cardiac monitoring and multi-vitals tracking capabilities. This strategic move is expected to strengthen iRhythm's long-term growth profile and become accretive to revenue growth by 2027, while also raising its fiscal 2026 sales guidance.
iRhythm Holdings, Inc. is acquiring VitalConnect, a developer of wearable biosensor technology, for $287.5 million. This acquisition is a significant strategic move for iRhythm, broadening its offerings in ambulatory cardiac monitoring and multi-vitals tracking, integrating FDA-cleared technology into its portfolio. The company expects this deal to strengthen its long-term growth and become accretive to revenue growth by 2027, while also maintaining its adjusted EBITDA margin target. This news, coupled with strong Q2 performance and raised fiscal 2026 sales guidance, presents a positive outlook for IRTC, indicating potential for accelerated top-line growth and improved margin profile, making it a key opportunity for traders looking at growth in the digital healthcare sector.